Working… Menu
Trial record 2 of 7 for:    apl-101

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04743505
Recruitment Status : Not yet recruiting
First Posted : February 8, 2021
Last Update Posted : August 25, 2021
Apollomics Inc.
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : July 31, 2026
Estimated Study Completion Date : July 31, 2026